Jastrzębska-Więsek Magdalena, Siwek Agata, Partyka Anna, Kubacka Monika, Mogilski Szczepan, Wasik Anna, Kołaczkowski Marcin, Wesołowska Anna
Department of Clinical Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Krakow, Poland.
Department of Pharmacobiology, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Krakow, Poland.
Neuropharmacology. 2014 Oct;85:253-62. doi: 10.1016/j.neuropharm.2014.05.036. Epub 2014 Jun 4.
The 5-HT6 is one of the most recent additions to the 5-HT receptor family. Its pharmacological profile and anatomical distribution is suggestive of a putative role in mood disorders. Most of preclinical evidence suggests an anxiolytic-like action of 5-HT6 receptor antagonists. Evaluation the anxiolytic-like effects of EMD 386088, a partial 5-HT6receptor agonist, and its putative mechanism of action in rats. EMD 386088, administered intraperitoneally at a dose of 2.5 mg/kg evoked specific anxiolytic-like activity in the automated version of the conflict drinking Vogel and the elevated plus-maze tests visible by increasing all parameters indicating a potential anti-anxiety effect. Its activity was blocked by the selective 5-HT6 receptor antagonist SB 271046, but not by the selective GABAA/benzodiazepine receptor antagonist flumazenil. EMD 386088 did not intensify an anxiolytic-like effect produced by diazepam in the elevated plus-maze test. These findings suggest that EMD 386088, a 5-HT6 receptor agonist, produces anxiolytic-like activity after systemic administration which may result from direct stimulation of 5-HT6 receptors.
5-羟色胺6(5-HT6)受体是5-羟色胺(5-HT)受体家族中最新发现的成员之一。其药理学特性和解剖学分布表明它在情绪障碍中可能发挥一定作用。大多数临床前证据表明5-HT6受体拮抗剂具有抗焦虑样作用。评估部分5-HT6受体激动剂EMD 386088在大鼠中的抗焦虑样作用及其可能的作用机制。以2.5mg/kg的剂量腹腔注射EMD 386088,在改良的Vogel冲突饮水试验和高架十字迷宫试验的自动化版本中诱发了特定的抗焦虑样活性,所有表明潜在抗焦虑作用的参数均增加。其活性被选择性5-HT6受体拮抗剂SB 271046阻断,但未被选择性GABAA/苯二氮䓬受体拮抗剂氟马西尼阻断。在高架十字迷宫试验中,EMD 386088没有增强地西泮产生的抗焦虑样作用。这些发现表明,5-HT6受体激动剂EMD 386088全身给药后产生抗焦虑样活性,这可能是直接刺激5-HT6受体的结果。